R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 39 PLN -1.27% Market Closed
Market Cap: 901.7m PLN
Have any thoughts about
Ryvu Therapeutics SA?
Write Note

Wall Street
Price Targets

RVU Price Targets Summary
Ryvu Therapeutics SA

Wall Street analysts forecast RVU stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RVU is 82.06 PLN with a low forecast of 69.19 PLN and a high forecast of 104.27 PLN.

Lowest
Price Target
69.19 PLN
77% Upside
Average
Price Target
82.06 PLN
110% Upside
Highest
Price Target
104.27 PLN
167% Upside
Ryvu Therapeutics SA Competitors:
Price Targets
EVT
Evotec SE
43% Upside
VIMTALABS
Vimta Labs Ltd
40% Downside
SHC
Sotera Health Co
24% Upside
301333
R&G PharmaStudies Co Ltd
33% Upside
SEER
Seer Inc
36% Upside
WAT
Waters Corp
5% Upside
QTRX
Quanterix Corp
89% Upside
DHR
Danaher Corp
28% Upside

Revenue
Forecast

Revenue Estimate
Ryvu Therapeutics SA

For the last 8 years the compound annual growth rate for Ryvu Therapeutics SA's revenue is 2%. The projected CAGR for the next 4 years is 25%.

2%
Past Growth
25%
Estimated Growth
Estimates Accuracy
-36%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Ryvu Therapeutics SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Net Income
Forecast

Net Income Estimate
Ryvu Therapeutics SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-37%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RVU's stock price target?
Price Target
82.06 PLN

According to Wall Street analysts, the average 1-year price target for RVU is 82.06 PLN with a low forecast of 69.19 PLN and a high forecast of 104.27 PLN.

What is Ryvu Therapeutics SA's Revenue forecast?
Projected CAGR
25%

For the last 8 years the compound annual growth rate for Ryvu Therapeutics SA's revenue is 2%. The projected CAGR for the next 4 years is 25%.

Back to Top